Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

Concept Medical Inc. Granted Breakthrough Device Designation for MagicTouch Sirolimus Coated Balloon
News | Drug-Eluting Balloons | May 02, 2019

May 2, 2019 — Concept Medical Inc. (CMI) has been granted Breakthrough Device Designation from the U.S. Food and...

Orchestra BioMed Receives FDA Breakthrough Device Designation for Virtue Sirolimus-eluting Balloon
Technology | Drug-Eluting Balloons | April 24, 2019

April 24, 2019 —  Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug...

News | Drug-Eluting Balloons | March 06, 2019

March 6, 2019 – Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food...

Philips Releases Three-Year Data on Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | January 28, 2019

January 28, 2019 — Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated...

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019

January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter...

Virtue Sirolimus-Eluting Balloon Demonstrates Positive Safety and Efficacy at Three Years
News | Drug-Eluting Balloons | September 25, 2018

September 25, 2018 — Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty...

Three-Year Real-World Data Support In.Pact Admiral as Primary PAD Therapy
News | Drug-Eluting Balloons | September 24, 2018

September 24, 2018 — New data announced at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept...

FDA Approves 200, 250 Millimeter In.Pact Admiral Drug Coated Balloons
Technology | Drug-Eluting Balloons | June 15, 2018

June 15, 2018 — Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm...

News | Drug-Eluting Balloons | May 29, 2018

May 29, 2018 – M.A. MedAlliance SA has raised $37 million to help develop and commercialize the first sirolimus...

The Medtronic In.Pact Admiral Paclitaxel-coated (DCB) Percutaneous Transluminal Angioplasty Balloon Catheter is now indicated for lesions up to 360 mm in length.
Technology | Drug-Eluting Balloons | May 03, 2018

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has expanded the indication for the Medtronic In.Pact ...

In.Pact Admiral Balloon Demonstrates Consistent, Durable Outcomes in LINC 2018 Studies
News | Drug-Eluting Balloons | February 07, 2018

February 7, 2018 — Medtronic plc recently added to its body of clinical evidence supporting the In.Pact Admiral...

The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons | November 02, 2017

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (...

Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | September 18, 2017

September 18, 2017 — Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (...

Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD) | September 13, 2017

September 13, 2017 — Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual...

Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons | September 13, 2017

September 13, 2017 — Medtronic plc announced that the In.Pact Admiral...

Overlay Init